
    
      This study enrolled nine HIV-infected adult subjects in three sequential dose cohorts. All
      had durable suppression of HIV-RNA on HAART over the previous 6 months and CD4 count over 300
      cells/mm3. Subjects, received on study Day 0 a single DermaVir immunization:

        -  Low dose: 0.1 mg pDNA, 0.8 mL DermaVir administered under two DermaPrep patches.

        -  Medium dose: 0.4 mg pDNA, 3.2 mL DermaVir administered under four DermaPrep patches.

        -  High dose: 0.8 mg pDNA, 6.4 mL DermaVir administered under eight DermaPrep patches.

      Subjects were on study for a total of 28 days followed by a post-treatment safety follow-up
      for 48 weeks. HAART was not interrupted. All subjects completed the 28-day treatment and 48
      weeks safety follow up phase.
    
  